801 Novel nanoparticles mediate efficient siRNA/mRNA co-delivery to melanoma

Checkpoint immunotherapy has revolutionized treatment for patients with advanced or metastatic melanoma; however, many patients ’ tumors either fail to respond or develop secondary resistance. As a result, there is an urgent need for an off-the-shelf local treatment that can improve therapeutic outcomes by increasing immune activation and reducing immunosuppressive factors. We developed a library of novel lipophilic poly(b eta-amino ester) (PBAE)-based biodegradable nanoparticle (NP) formulations with different backbone, sidechain, and endcap monomers and various lipophilic/linear ratios to efficiently co-deliver mRNA and siRNA to melanoma cells in a single formulation.

Source: Journal of Investigative Dermatology - April 17, 2023 Category: Dermatology Authors: K.M. Luly, E.E. Rocher, J.J. Green, S.Y. Tzeng, J.C. Sunshine Source Type: research